Urine Drugs of Abuse
[Urine Drugs of Abuse ]
EPTIS factsheet 187906 | Last revision 2024-05-22 | URL: https://www.eptis.bam.de/pts187906 https://www.eptis.bam.de/pts187906
| PT provider | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| PT provider | Weqas Weqas | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Based in | United Kingdom | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Language(s) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Remarks | The initial analysis is a screening test for commonly abused drug groups, e.g opiates, benzodiazepines, barbiturates, cannabinoids, amphetamines and cocaine, drugs used in the treatment of opiate addiction (methadone and buprenorphine) and novel psychoactive substances. Initial screens are based on immunoassays (laboratory and POCT) with a further confirmatory analysis in a laboratory using GC-MS. The use of Gravimetric ‘weighed in’ values as a performance target in EQA data provides a stable, independent target that is not influenced by the overall or method mean. The linear panel of samples are distributed on a number of occasions facilitating the assessment of linearity, within and between batch precision and traceability, providing laboratories with ongoing evidence for their compliance to ISO 15189. Eighteen samples are distributed annually. Key Features: - Samples include different panels of drug / metabolites. Linear samples cover analytical and clinically relevant ranges including at or near lower limit of detection for qualitative methods. - Suitable for qualitative and quantitative results. - Suitable for both laboratory and POCT devices. - Traceable, “gravimetric” concentration of metabolite and 1° drug. - Programme assesses both laboratory and method performance, including, linearity (recovery to gravimetric), specificity, bias, within and between batch imprecision. For more information: https://www.weqas.com/participantzone/subscription-charges/ or contact@weqas.com | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Keywords | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Product groups |
Health care / medical devices
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Testing fields |
Medical analysis
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Technical details | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aims of the PT scheme | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Target group of participants | Urine testing for both prescribed and illicit drugs is increasingly used in both Laboratory and Point of Care settings. | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Linked to specific legislation / standards | UKAS ISO/IEC 17043 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional, subsidiary aims | validation of testing methods | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Number of participants | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 |
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Operation is commissioned / requested by | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fees and frequency | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Regularly operated | Yes (Frequency: Bimonthly. Samples: 3 x 3.0mL. ) | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Year of first operation | 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Contact details of the PT provider | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Provider | Contact person | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||||||||||||||||||||||||||||||||||||||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.